138 related articles for article (PubMed ID: 30909855)
1. Challenges of using lipopolysaccharides for cancer immunotherapy and potential delivery-based solutions thereto.
Shetab Boushehri MA; Lamprecht A
Ther Deliv; 2019 Mar; 10(3):165-187. PubMed ID: 30909855
[TBL] [Abstract][Full Text] [Related]
2. TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings.
Shetab Boushehri MA; Lamprecht A
Mol Pharm; 2018 Nov; 15(11):4777-4800. PubMed ID: 30226786
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Nanostructure-Based Lipopolysaccharide Active Immunotherapy in Cancer: Size and Composition Determine Short- and Long-Term Tolerability.
Shetab Boushehri MA; Yazeji T; Stein V; Lamprecht A
Mol Pharm; 2019 Nov; 16(11):4507-4518. PubMed ID: 31532690
[TBL] [Abstract][Full Text] [Related]
4. A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides.
Shetab Boushehri MA; Abdel-Mottaleb MMA; Béduneau A; Pellequer Y; Lamprecht A
Drug Deliv; 2018 Nov; 25(1):1414-1425. PubMed ID: 29902933
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
[TBL] [Abstract][Full Text] [Related]
6. Engineering nanoparticle strategies for effective cancer immunotherapy.
Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticulate immunotherapy for cancer.
Kapadia CH; Perry JL; Tian S; Luft JC; DeSimone JM
J Control Release; 2015 Dec; 219():167-180. PubMed ID: 26432555
[TBL] [Abstract][Full Text] [Related]
8. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4.
Chicoine MR; Zahner M; Won EK; Kalra RR; Kitamura T; Perry A; Higashikubo R
Neurosurgery; 2007 Feb; 60(2):372-80; discussion 381. PubMed ID: 17290189
[TBL] [Abstract][Full Text] [Related]
9. Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer.
Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
Curr Pharm Des; 2015; 21(29):4201-16. PubMed ID: 26323429
[TBL] [Abstract][Full Text] [Related]
10. Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-γ.
Okuyama H; Tominaga A; Fukuoka S; Taguchi T; Kusumoto Y; Ono S
Oncol Rep; 2017 Feb; 37(2):684-694. PubMed ID: 28075473
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway.
Zhang S; Yang N; Ni S; Li W; Xu L; Dong P; Lu M
Int J Clin Exp Pathol; 2014; 7(10):6626-34. PubMed ID: 25400741
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy.
Mei Y; Wang R; Jiang W; Bo Y; Zhang T; Yu J; Cheng M; Wu Y; Cheng J; Ma W
Biomater Sci; 2019 Jun; 7(7):2640-2651. PubMed ID: 31090764
[TBL] [Abstract][Full Text] [Related]
13. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery.
Jin Q; Liu Z; Chen Q
J Control Release; 2021 Jan; 329():882-893. PubMed ID: 33053396
[TBL] [Abstract][Full Text] [Related]
14. Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.
Hong E; Dobrovolskaia MA
Adv Drug Deliv Rev; 2019 Feb; 141():3-22. PubMed ID: 29339144
[TBL] [Abstract][Full Text] [Related]
15. Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer.
Cheng CT; Castro G; Liu CH; Lau P
Clin Chim Acta; 2019 May; 492():12-19. PubMed ID: 30711524
[TBL] [Abstract][Full Text] [Related]
16. Asparagine attenuates hepatic injury caused by lipopolysaccharide in weaned piglets associated with modulation of Toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling and their negative regulators.
Wu H; Liu Y; Pi D; Leng W; Zhu H; Hou Y; Li S; Shi H; Wang X
Br J Nutr; 2015 Jul; 114(2):189-201. PubMed ID: 26079268
[TBL] [Abstract][Full Text] [Related]
17. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells.
Olbert PJ; Kesch C; Henrici M; Subtil FS; Honacker A; Hegele A; Hofmann R; Hänze J
Urol Oncol; 2015 Mar; 33(3):110.e19-27. PubMed ID: 25499923
[TBL] [Abstract][Full Text] [Related]
18. Klotho preservation by Rhein promotes toll-like receptor 4 proteolysis and attenuates lipopolysaccharide-induced acute kidney injury.
Bi F; Chen F; Li Y; Wei A; Cao W
J Mol Med (Berl); 2018 Sep; 96(9):915-927. PubMed ID: 29730698
[TBL] [Abstract][Full Text] [Related]
19. Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery.
Huynh V; Jesmer AH; Shoaib MM; D'Angelo AD; Rullo AF; Wylie RG
Chembiochem; 2019 Mar; 20(6):747-753. PubMed ID: 30426647
[TBL] [Abstract][Full Text] [Related]
20. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
